Clinical trials: Cardiovascular Event
Anticoagulant Drugs, Antiplatelet Drug
Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD
Patients with PAD were grouped according to the combination of different anticoagulant and antiplate drugs. The type, dosage and duration of anticoagulant and antiplatelet drugs were recorded after operation.
- Conditions
- Anticoagulant Drugs, Antiplatelet Drug, Peripheral Arterial Disease
- Trial name
- NCT05852197
- Testing
- anticoagulant or antiplatelet drugs
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Prediabetes, Coronary Artery Disease
Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease
Objectives: The investigators examined whether rosiglitazone, a thiazolidinedione (TZD), is beneficial for pre-diabetes mellitus (DM) adults with documented coronary artery disease (CAD).
- Conditions
- Prediabetes, Coronary Artery Disease, Insulin Resistance, Glucose Intolerance
- Trial name
- NCT01574820
- Testing
- rosiglitazone (4 mg)/day
- Volunteers
- 105 people
- Sponsor
- National Cheng-Kung University Hospital
Kidney Diseases, End-Stage Kidney Disease
Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag)
Many patients on hemodialysis have low levels of magnesium. Magnesium is needed to keep the heart, kidneys, and other organs working properly.
- Conditions
- Kidney Diseases, End-Stage Kidney Disease, Hemodialysis
- Trial name
- NCT04079582
- Testing
- Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L)., Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).
- Where
- Canada
- Volunteers
- 25,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cardiac Event, Klinefelter Syndrome
TyG Index Levels in Klinefelter Syndrome
It is well known that the frequency of cardiometabolic diseases are increased in patients with Klinefelter Syndrome. The triglyceride-glucose index (TyG index) is a simple surrogate marker of insulin resistance and is also…
- Conditions
- Cardiac Event, Klinefelter Syndrome, Endothelial Dysfunction
- Trial name
- NCT05014997
- Testing
- no intervention
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- NCT06292013
- Testing
- Lepodisiran Sodium
- Where
- 928 sites in United States, Argentina and 26 more
- Volunteers
- 17,300 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Event, Coronary Artery Bypass Graft
Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)
Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity.
- Conditions
- Cardiovascular Event, Coronary Artery Bypass Graft, Diabetes Mellitus
- Trial name
- NCT03590223
- Testing
- Coronary Bypass Revascularization
- Where
- Switzerland
- Volunteers
- 589 people
- Sponsor
- University Hospital, Basel, Switzerland
Intracranial Aneurysm
Guided Antiplatelet Therapy in Interventional Treatment of Intracranial Aneurysms
The use of intracranial stents expands the possibilities for endovascular treatment of intracranial aneurysms and improves the success rate. However, it also increases the risk of ischemic complications in patients.
- Trial name
- GATITIA (NCT05825391)
- Testing
- Adjustment of Antiplatelet Drugs
- Where
- 2 sites in China
- Volunteers
- 590 people
- Sponsor
- Beijing Tiantan Hospital
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a…
- Trial name
- NCT01627327
- Testing
- fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
The aim of this study is to evaluate the effect of bortezomib in combination with dexamethasone and zoledronic acid on bone mineral density (BMD) and skeletal related events (SREs) in Patients with Multiple Myeloma who Have…
- Trial name
- NCT00972959
- Testing
- Bortezomib, Zoledronic Acid, Dexamethasone
- Where
- 3 sites in Greece
- Volunteers
- 17 people
- Sponsor
- University of Athens
Atherosclerosis, Cardiovascular Diseases
Plaque Registration and Event Detection In Computed Tomography
Disruption of an atherosclerotic plaque is responsible for at least two-thirds of acute coronary syndrome. Thus, identification of plaques vulnerable to rupture has become important.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- PREDICT (NCT00991835)
- Where
- Japan
- Volunteers
- 3,015 people
- Sponsor
- Hiroshima University
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
HIV, Hypercholesterolemia
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
The objective of this study is to evaluate changes in Framingham score (from low to moderate, from moderate to high) based on changes in lipid profile and other parameters from baseline to 48 weeks of HAART in naïve patients or…
- Conditions
- HIV, Hypercholesterolemia, Dyslipidemia
- Trial name
- NCT01705873
- Where
- Argentina
- Volunteers
- 300 people
- Sponsor
- Helios Salud
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atrial Fibrillation, Cardioembolic Events
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Oral anticoagulation treatment (OAC) following clinically successful catheter abla-tion of atrial fibrillation (AF) is controversial.
- Conditions
- Atrial Fibrillation, Cardioembolic Events, Oral Anticoagulation
- Trial name
- ODIn-AF (NCT02067182)
- Testing
- Dabigatran
- Where
- 19 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Georg Nickenig
Type2 Diabetes, Myocardial Infarction
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events
The purpose of this study is to compare the risk of cardiovascular events associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among…
- Conditions
- Type2 Diabetes, Myocardial Infarction, Ischemic Stroke, Cardiovascular Death
- Trial name
- NCT03939624
- Testing
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Where
- Canada
- Volunteers
- 419,734 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Frailty, Elderly
Frailty of Elderly With Valvular Heart Disease and the Short Term Adverse Events
Despite the rapid development of medical and nursing technology, the prognosis of valvular heart disease has been greatly improved.
- Conditions
- Frailty, Elderly, Valvular Heart Disease
- Trial name
- NCT05014750
- Testing
- None intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Zhongshan Hospital
Cardiac Arrest
Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events
The goal of this study is to test the feasibility and acceptability of an informational website to reduce uncertainty, psychological distress, and caregiver burden among close family members of cardiac arrest patients.
- Trial name
- RESURFACE (NCT06048068)
- Testing
- Educational Informational Platform
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Stent Embolisation
Efficacy and Safety of StENt-assisted Treatment for CErebral Aneurysms
Prospective registry study to evaluate safety and efficacy of stent assisted embolization of intracranial aneurysm.
- Trial name
- NCT01702584
- Testing
- stent assisted embolization
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Kobe City General Hospital
Hypogonadism, Cardiovascular Diseases
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
- Trial name
- TRAVERSE (NCT03518034)
- Testing
- AndroGel®
- Where
- 384 sites in United States, Puerto Rico
- Volunteers
- 5,246 people
- Sponsor
- AbbVie
Hypertension
Impact of Training of GPs on Adherence of Hypertensive Individuals to Antihypertensive Medication
This study aims to assess the impact of training General Practitioners (GPs) on adherence to antihypertensive medication among hypertensive individuals. It also aims to assess risk factors for non-adherence.
- Trial name
- NCT00330408
- Testing
- GP training
- Where
- Pakistan
- Volunteers
- 178 people
- Sponsor
- Aga Khan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.